---
title: "Lysergide (DT120) in Generalized anxiety disorder: Psychological therapies"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Psychological therapies. Topics: NICE guideline: low-intensity psychological interventions at step 2, NICE guideline: CBT or applied relaxation at step 3, WFSBP guideline: CBT as first-line psychotherapy, CANMAT guideline: efficacy of CBT and other psychological treatments, and 6 further topics. 10 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/psychological-therapies"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Psychological therapies

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Psychological Therapies

<a id="topic-2.2.2.1.1-1"></a>

### NICE guideline: low-intensity psychological interventions at step 2

> “For people with GAD whose symptoms have not improved after education and active monitoring in step 1, offer 1 or more of the following as a first-line intervention, guided by the person's preference:”
> “individual non-facilitated self-help”
> “individual guided self-help”
> “psychoeducational groups. [2011]”
> “be based on the treatment principles of CBT”
> “usually consist of 5 to 7 weekly or fortnightly face-to-face or telephone sessions, each lasting 20 to 30 minutes. [2011, amended 2018]”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.1-2"></a>

### NICE guideline: CBT or applied relaxation at step 3

> “For people with GAD and marked functional impairment, or those whose symptoms have not responded adequately to step 2 interventions:”
> “Base the choice of treatment on the person's preference as there is no evidence that either mode of treatment (individual high-intensity psychological intervention or drug treatment) is better. [2011]”
> “If a person with GAD chooses a high-intensity psychological intervention, offer either CBT or applied relaxation. [2011]”
> “usually consist of 12 to 15 weekly sessions (fewer if the person recovers sooner; more if clinically required), each lasting 1 hour. [2011]”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.1-3"></a>

### WFSBP guideline: CBT as first-line psychotherapy

> “Cognitive behavioural therapy (CBT) is the first-line psychotherapy for anxiety disorders.”

Source: [Bandelow et al. (2023)](https://www.tandfonline.com/doi/full/10.1080/15622975.2022.2086295)

<a id="topic-2.2.2.1.1-4"></a>

### CANMAT guideline: efficacy of CBT and other psychological treatments

> “Meta-analyses clearly demonstrate that CBT significantly reduces GAD symptoms and is markedly more effective than placebo or wait-list control conditions for GAD (Level 1)”
> “Few studies have compared CBT and pharmacotherapy alone in the same trial, but the magnitude of benefits appear to be comparable for both groups”
> “A meta-analysis of five trials found no significant differences between CBT and relaxation therapy”
> “However, more recent studies suggest that applied relaxation has limited efficacy”
> “CBT is an effective first-line option for the treatment of GAD and is as effective as pharmacotherapy. Internet-based and computer-based CBT have also demonstrated efficacy. Evidence does not support the routine combination of CBT and pharmacotherapy, but when patients do not benefit from CBT, a trial of pharmacotherapy is advisable, and vice versa.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.1-5"></a>

### CANMAT guideline: durability of benefit after psychological treatment

> “suggest that benefits of psychological treatments are maintained at one to three years follow-up after treatment.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.1-6"></a>

### BAP guideline: psychological treatments compared with drug treatment

> “psychological: cognitive-behaviour therapy, applied relaxation [A]”
> “Pharmacological or psychological treatments, when delivered singly, have broadly similar efficacy in acute treatment”
> “The efficacy of CBT and applied relaxation appears superior to that of other psychological interventions”
> “but the comparative efficacy of pharmacological and psychological approaches over the long-term is not established.”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.1-7"></a>

### U.S. primary care review: psychotherapy techniques and comparative effectiveness

> “Psychotherapy for GAD and PD can include relaxation techniques; cognitive restructuring, including CBT; and exposure therapy.”
> “Psychotherapy is as effective as pharmacotherapy for treating PD and GAD and can be used alone or combined with pharmacotherapy for anxiety disorders, with combination treatment likely to be more effective than either treatment alone.”
> “Of the psychotherapy techniques that have been studied for GAD and PD, CBT appears to be the most effective.”
> “Limited evidence suggests that therapist-supported internet CBT, which can expand access to therapy, is effective, but comparisons with alternative therapies are limited.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.2.1.1-8"></a>

### Meta-analysis of psychotherapy and medication trials: 79 randomized trials

> “Seventy-nine randomized controlled trials (RCT) including 11,002 participants with a diagnosis of GAD were included in a meta-analysis that tested the efficacy of psychotherapies or medications for GAD.”
> “Consistent with prediction, evidence-based psychotherapies outperformed control conditions on primary outcome measures at posttreatment with a medium to large effect size (g = 0.76, 95% CI: 0.61–0.91, p < 0.001).”
> “Within psychotherapy comparisons, pill placebo-controlled studies had the highest effect size (n = 3, g = 1.44, 95% CI: 0.94–1.94, p < 0.001), followed by WL controls (n = 22, g = 0.90, 95% CI: 0.73–1.08, p < 0.001), psychological placebo (n = 10, g = 0.47, 95% CI: 0.25–0.69, p < 0.001), and TAU (n = 5, g = 0.38, 95% CI: 0.05–0.71, p < 0.05;”
> “There was evidence of publication bias in psychotherapy studies.”
> “Because medication studies had more placebo control conditions than inactive conditions compared to psychotherapy studies, effect sizes between the domains should not be compared directly.”

Source: [Carl et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7063818/)

<a id="topic-2.2.2.1.1-9"></a>

### Meta-analysis of psychotherapy trials: 41 studies

> “A total of 41 studies (with 2132 patients meeting diagnostic criteria for GAD) were identified through systematic searches in bibliographical databases, and were included in the meta-analysis.”
> “Most studies examined the effects of cognitive behavior therapy (CBT).”
> “The pooled effect of the 38 comparisons (from 28 studies) of psychotherapy versus a control group was large (g=0.84; 95% CI: 0.71-0.97) with low to moderate heterogeneity.”
> “There were some indications that CBT was also effective at follow-up and that CBT was more effective than applied relaxation in the longer term.”

Source: [Cuijpers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24487344/)

<a id="topic-2.2.2.1.1-10"></a>

### Meta-analysis across anxiety disorders: pre-post effect sizes of psychotherapies and medications

> “Pre-post and treated versus control effect sizes (ES) were calculated for all evaluable randomized-controlled studies (n = 234), involving 37,333 patients.”
> “Medications were associated with a significantly higher average pre-post ES [Cohen's d = 2.02 (1.90-2.15); 28,051 patients] than psychotherapies [1.22 (1.14-1.30); 6992 patients; P < 0.0001].”
> “Individual CBT was more effective than waiting list, psychological placebo and pill placebo.”
> “Pre-post ES for psychotherapies did not differ from pill placebos; this finding cannot be explained by heterogeneity, publication bias or allegiance effects.”

Source: [Bandelow et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25932596/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
